A PSEN2 genetic test is a lab assay that reads the DNA sequence of the PSEN2 gene, looking for mutations known to cause early-onset Alzheimer's disease. It does not measure amyloid plaques, tau tangles, or any protein in the brain — it only checks whether the gene's instructions themselves carry an error. The test matters most for families with a strong pattern of early-onset dementia, not for the general population worried about ordinary aging. Understanding what it can and cannot tell you helps separate a genuinely useful answer from a result that creates more uncertainty than it resolves.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the PSEN2 Test Actually Analyzes
- Who This Test Is Actually For
- Insurance Coverage and When It's Considered Necessary
- Why PSEN2 Results Are Often Unclear
- What PSEN2 Testing Does Not Replace
- What a Positive Result Means for Family Planning
- Frequently Asked Questions
What the PSEN2 Test Actually Analyzes
The clinical PSEN2 test sequences every coding exon of the gene along with the boundaries where exons meet introns, searching for point mutations and small insertions or deletions, according to PreventionGenetics' test description. It is a DNA-level read, not a scan of brain tissue or spinal fluid.
PSEN2 is one of three genes tied to presenilin biology; it encodes a protein involved in processing amyloid precursor protein (APP). Pathogenic PSEN2 variants shift that processing toward a longer, stickier form of amyloid-beta, amyloid-beta 42, which aggregates more readily and drives autosomal dominant early-onset familial Alzheimer's disease, per the Radboudumc test description. Because PSEN2 has no documented large deletions or duplications, the test skips copy-number analysis entirely — it would add cost without adding diagnostic value for this particular gene, the same source notes.
Who This Test Is Actually For
PSEN2 mutations are rare even within familial Alzheimer's disease, accounting for roughly 5% of early-onset familial cases — far less common than mutations in PSEN1, according to PreventionGenetics. This is not a test ordered because someone in their 70s is forgetful; it targets families with a multi-generational pattern of dementia starting well before age 65.
The best-studied PSEN2 mutation, N141I, is a founder variant found almost exclusively in families descended from Volga German settlers. Its clinical penetrance runs around 95% — high, but not complete — and a handful of documented carriers have reached their late 80s while remaining cognitively intact, according to a study indexed in PMC. That incomplete penetrance distinguishes PSEN2 from PSEN1, whose mutations are essentially fully penetrant.
- Strong candidate: multiple relatives across generations diagnosed with dementia in their 50s or 60s, especially with ancestry tied to known founder populations.
- Weak candidate: a single relative with typical late-onset Alzheimer's in their 70s or 80s and no other family history.
Insurance Coverage and When It's Considered Necessary
Insurers distinguish sharply between testing for a mutation already identified in a family and testing to assess personal risk from scratch. Blue Shield of California's 2024-2025 policy considers targeted PSEN1/PSEN2/APP testing medically necessary for relatives of a known carrier, or for early-onset patients whose family mutation hasn't yet been identified, and it strongly recommends genetic counseling both before and after testing, per Blue Shield's medical policy.
Outside that familial context, coverage narrows considerably. FEP Blue's 2025-2026 policy treats PSEN2 testing for asymptomatic risk assessment as investigational when there's no known family mutation to confirm, according to FEP Blue's medical policy #20413. That same policy requires a separate test, APOE genotyping, specifically to determine eligibility for FDA-approved amyloid-targeting therapies in mild cognitive impairment or mild Alzheimer's dementia — PSEN2 results play no role in that decision.
Why PSEN2 Results Are Often Unclear
A meaningful share of PSEN2 variants don't resolve into a clean "positive" or "negative" answer. A systematic re-evaluation of 63 PSEN2 variants under standard ACMG-AMP criteria found that different laboratories sometimes classify the identical variant differently — one lab calling a missense change pathogenic based on protein modeling, another calling the same change a variant of uncertain significance — usually because family segregation data is too thin to settle the question, according to the PMC re-evaluation study.
A variant of uncertain significance is not a diagnosis in either direction. It neither confirms an inherited cause of dementia nor rules one out, as illustrated by submissions on a specific PSEN2 variant tracked in ClinVar Miner. A negative or inconclusive PSEN2 result also says nothing about risk for ordinary, sporadic late-onset Alzheimer's — the test was never built to assess that form of the disease at all.
What PSEN2 Testing Does Not Replace
PSEN2 sequencing is a different tool from APOE ε4 testing, and the two aren't interchangeable. APOE ε4 is a common risk-modifying gene variant relevant to both early- and late-onset sporadic Alzheimer's, and it's also used to stratify risk before anti-amyloid drug treatment — but carrying it doesn't guarantee disease the way a pathogenic PSEN2 mutation does, according to a genetic-testing overview from BioSpace.
A PSEN2 panel will not surface APOE status, and an APOE panel will not surface a PSEN2 mutation. The two tests also answer different clinical questions: PSEN2 looks for a deterministic cause within a single family, while APOE describes a population-level risk gradient that applies broadly. Ordering one does not substitute for the other, and a workup aimed at explaining early-onset dementia in a family may need both, guided by the specific question being asked.
What a Positive Result Means for Family Planning
PSEN2-related disease tends to present later than PSEN1-related disease, commonly in a carrier's 50s or 60s, and more often includes neuropsychiatric features such as hallucinations or delusions alongside memory loss, according to PreventionGenetics' clinical summary. A confirmed pathogenic result doesn't stand alone as a diagnosis — it establishes a 50% recurrence risk for each child of a carrier, which is why standard clinical genetics guidance calls for genetic counseling around the result rather than treating the lab report as the final word. That counseling conversation typically covers reproductive options, timing of disclosure to other relatives, and how the specific variant's penetrance — not just its presence — shapes what the result actually predicts for that individual.
Frequently Asked Questions
Does a negative PSEN2 result rule out Alzheimer's disease?
No. It only rules out mutations in that one gene; it says nothing about sporadic late-onset Alzheimer's, which PSEN2 testing isn't designed to detect, per PreventionGenetics.
Is PSEN2 testing the same as APOE testing?
No. PSEN2 looks for a rare, often deterministic mutation within a family; APOE ε4 is a common risk-modifying variant used more broadly, including for anti-amyloid drug eligibility, according to BioSpace.
Will insurance cover PSEN2 testing for someone with no family history of early-onset dementia?
Often not. Testing for asymptomatic risk assessment outside a known familial mutation is treated as investigational under policies like FEP Blue's, per FEP Blue's medical policy.
